Drug intelligence / Profile preview

NUV-244

Development stage
Preclinical
Lead developer
Nuvisan ICB
Modality
PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01

Overview

NUV-244 is a potent and selective small-molecule degrader of the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M variant. The I148M mutation is a well-established genetic determinant of fatty liver disease and has emerging implications in cancer biology, particularly in metabolic reprogramming and hepatocellular carcinoma (HCC). NUV-244 functions by inducing the targeted degradation of the PNPLA3 I148M protein, serving as a pharmacological tool to investigate the oncogenic and tumor-modulatory roles of this variant. Preclinical studies have demonstrated that NUV-244 treatment can modulate cancer cell transcriptomics, proteomics, mitochondrial function, and survival, highlighting its potential to create selective vulnerabilities in cancer cells with metabolic plasticity.

02

Targets

PNPLA3 I148M (Patatin-like phospholipase domain-containing protein 3 I148M variant)E3 ligase (E3 ubiquitin ligases)

Beyond the preview

Go deeper on NUV-244.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NUV-244.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call